Skip to content

Clinical Evaluation of the NeoPill Device for Reduction of Oral Bacterial Load in Patients With Fixed Orthodontic Appliances

Clinical Evaluation of the NeoPill Device for Reduction of Oral Bacterial Load in Patients With Fixed Orthodontic Appliances

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07355400
Enrollment
15
Registered
2026-01-21
Start date
2025-12-09
Completion date
2026-04-01
Last updated
2026-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Plaque

Keywords

Dental plaque, Oral bacterial load, Orthodontic appliances, Oral hygiene device, Mechanical oral cleaning

Brief summary

This study evaluates the effectiveness of the NeoPill oral hygiene device in reducing oral bacterial load in adults wearing fixed orthodontic appliances. Maintaining oral hygiene is challenging for orthodontic patients due to limited access around brackets and wires, and current solutions often rely on chemical-based products and disposable tools. NeoPill is a reusable, battery-operated oral device designed to provide mechanical cleansing of the oral cavity. In this single-arm clinical evaluation, participants will undergo oral swab sampling before and immediately after a single 30-second application of the NeoPill device. The primary outcome is the change in aerobic bacterial load, measured as colony-forming units (CFUs), between pre- and post-treatment samples. Participants will also complete a short questionnaire to assess usability, comfort, and overall experience with the device. The study aims to generate preliminary clinical and user-experience data to support further development of the NeoPill device.

Detailed description

This is a single-arm, pre-post interventional clinical evaluation designed to assess the effectiveness of the NeoPill device in reducing aerobic bacterial load in the oral cavity of adults with fixed orthodontic appliances. The study will be conducted at the German Medical Institute in Limassol, Cyprus, and will enroll approximately 15 to 20 participants aged 18 years or older. Eligible participants must be currently wearing fixed orthodontic appliances and able to provide informed consent. Exclusion criteria include recent antibiotic use, active oral infections, immunocompromised status, or systemic conditions that may affect oral flora. After providing written informed consent, participants will undergo baseline oral swab collection from gingival areas and around orthodontic brackets on the upper second premolars. A trained research technician or nurse will then apply the NeoPill device for a standardized duration of 30 seconds, ensuring consistent positioning and technique across participants. Immediately following device application, a second oral swab will be collected from the same anatomical sites. Both swab samples will be transported under controlled conditions to an accredited microbiology laboratory at the German Medical Institute, where aerobic culturing will be performed to quantify colony-forming units (CFUs). The primary outcome measure is the difference in CFU counts between pre- and post-intervention samples. Statistical analysis will be conducted using a Wilcoxon Signed Rank Test with a significance threshold of p \< 0.05. Following sample collection, participants will complete a structured questionnaire assessing comfort, usability, perceived experience, and willingness to use the NeoPill device regularly. Questionnaire data and laboratory results will be linked using study-specific identifiers and stored securely within a GDPR-compliant digital platform. The study involves minimal risk to participants, limited primarily to temporary discomfort during swab collection or device use. No chemical agents or systemic interventions are involved. All data will be pseudonymised prior to analysis, and only anonymised results will be shared with the device manufacturer.

Interventions

DEVICENeoPill Oral Hygiene Device

The NeoPill is a reusable, battery-operated oral hygiene device applied intraorally for a standardized duration of 30 seconds. In this study, the device is applied once by trained study personnel. The intervention involves no chemical agents and no systemic exposure. The device is used to mechanically clean the oral cavity prior to post-intervention oral swab collection.

Sponsors

Neofunction d.o.o.
Lead SponsorINDUSTRY
German Oncology Center, Cyprus
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

This is a single-arm, pre-post interventional study in which all participants receive a single standardized 30-second application of the NeoPill device. Oral bacterial load is assessed before and immediately after the intervention using paired oral swab samples.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adults aged 18 years or older * Currently wearing fixed orthodontic appliances * Able and willing to provide written informed consent * Able to comply with study procedures during a single study visit

Exclusion criteria

* Use of systemic antibiotics within the past 2 weeks * Presence of active oral infections * Known immunocompromised status * Presence of systemic medical conditions that may affect oral bacterial flora

Design outcomes

Primary

MeasureTime frameDescription
Change in aerobic oral bacterial loadImmediately before and immediately after the intervention (same study visit)Difference in aerobic bacterial colony-forming unit (CFU) counts measured from oral swab samples collected immediately before and immediately after a single 30-second application of the NeoPill device.

Secondary

MeasureTime frameDescription
Participant-reported usability and comfort of the NeoPill deviceImmediately after device use (same study visit)Participant-reported usability and comfort are assessed using a NeoPill Participant Usability and Comfort Questionnaire, a structured, study-specific survey administered immediately after device use. The composite usability score is derived from Likert-scale items assessing overall experience, discomfort/pain, and likelihood of future use. \- Overall experience is rated on a 5-point Likert scale ranging from 1 (Very Unpleasant) to 5 (Very Pleasant). Higher scores indicate a more positive user experience. \- Discomfort or pain during device use is rated on a 5-point Likert scale ranging from 1 (No Pain) to 5 (Severe Pain). Higher scores indicate greater discomfort. \- Likelihood of regular future use is rated on a 5-point Likert scale ranging from 1 (Very Unlikely) to 5 (Very Likely). Higher scores indicate greater acceptability and usability. Responses are combined descriptively to evaluate overall usability and comfort of the NeoPill device.

Countries

Cyprus

Contacts

CONTACTGeorgina Kyriakoudes
aria@myaria.health+35795112337
CONTACTConstantinos Zamboglou
validate@gmic-eu.com00357 25208000
STUDY_DIRECTORConstantinos Zamboglou

GMIC

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 10, 2026